ReviewCurrent pharmaceutical design2026
Exploring Latest Expansions in Solid Lipid-based Nanoparticle Technology for Treatment of Cancer.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of cancer therapy has witnessed significant strides with the emergence of innovative drug delivery systems and one such promising avenue is solid lipid-based nanoparticle (SLN) technology. This abstract provides a complete overview of current advances in developing SLNs for effective cancer treatment solid lipid nanoparticles (NPs) represent a novel drug delivery platform characterized by their unique composition which includes biocompatible lipids as the main carrier material. This technology addresses challenges related to standard chemotherapy such as low bioavailability limited medicine stability and non-specific targeting. The incorporation of lipids in SLNs ensures enhanced drug encapsulation, protection of therapeutic agents from degradation-controlled release profiles. Recent breakthroughs in SLN technology have focused on optimizing formulation parameters to achieve superior drug loading capacities stability and sustained release kinetics. Advanced fabrication techniques including high-pressure homogenization and microemulsion methods have been pivotal in tailoring SLN properties for specific cancer types and therapeutic agents. Furthermore, SLNs' capacity to passively build up in tumor tissues using increased penetration and retention effects has been harnessed for targeted drug transport. Surface modifications using ligands or antibodies to facilitate active targeting, enhancing medication delivery's selectivity to tumor cells decreasing unwanted effects on normal tissues. This abstract highlights recent preclinical and clinical studies demonstrating the efficacy of SLN- based formulations in enhancing the therapeutic outcomes of various anticancer agents. The versatile nature of SLN technology makes it a viable option for the advancement of personalized and precision cancer therapies, marking a significant stride toward overcoming the limitations of conventional cancer treatments. As research in this domain progresses, the integration of SLNs holds immense potential for revolutionizing tumor treatment strategies.
Indexed as
Identifiers
39917937What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.